CV-6504.Hcl

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: CV-6504.Hcl
• 英文别名: 2,3,5-trimethyl-6-(pyridin-3-ylmethyl)cyclohexa-2,5-diene-1,4-dione;hydrochloride
• 化学式: C15H16ClNO2
• 分子量: 277.74
• InChiKey: FBOCJGYMOAAFSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.85
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,3,5-三甲基-6-(吡啶-3-基甲基)环己-2,5-二烯-1,4-二酮 生成 CV-6504.Hcl
  参考文献：
  名称：

  TERAO, SHINJI;NISHIKAWA, KOHEI

  摘要：

  DOI：

文献信息

• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。
• PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Vidal Juan Bernat

  公开号：US20100273757A1

  公开（公告）日：2010-10-28

  The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 represent hydrogen or specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.

  本发明提供了一种式为（I）的化合物，其中：A代表可选取代的单环或多环芳基或杂芳基基团；B代表可选取代的单环含氮杂芳基基团；并且要么a）R1和R2代表氢或指定的取代基，要么b）R2，R1和R1连接的—NH—基团形成从式（IIa）和（IIb）中选择的基团：（IIa）这些化合物可用作A2B受体拮抗剂，例如在哮喘治疗中。
• Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
  申请人：The Ludwig Institute for Cancer Research

  公开号：EP2548578A1

  公开（公告）日：2013-01-23

  The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs or characterized by excessive or inadequate FATP expression or activity. In particular, the present inventions concerns an anti-VEGF-B antibody or anti-sense oligonucleotide that inhibits VEGF-B transcription or translation for use in treating dyslipidemia in a human subject.

  本发明提供了调节体内 FATP 表达和/或活性的材料和方法。这些材料和方法对受 FATP 影响或以 FATP 表达或活性过度或不足为特征的各种疾病和病症有许多诊断、预防和治疗用途。特别是，本发明涉及一种抑制血管内皮生长因子-B 转录或翻译的抗血管内皮生长因子-B 抗体或抗有义寡核苷酸，用于治疗人体血脂异常。
• Anti-microbial peptides
  申请人：TENSIVE CONTROLS, INC.

  公开号：US10954271B2

  公开（公告）日：2021-03-23

  Described herein are anti-microbial peptides having enhanced activity and transport.

  本文描述的抗微生物肽具有更强的活性和转运能力。
• Cyclic peptides for treatment of cachexia
  申请人：Sharma D. Shubh

  公开号：US20060014194A1

  公开（公告）日：2006-01-19

  A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formula where R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

  一种高选择性黑色素皮质素-4 受体拮抗剂环六肽，其式为 式中 R 1 , R 2 , R 3a , R 3b , R 4 , R 5 x、y 和 z 如说明书中所定义，以及一种治疗体重失调（包括恶病质、肌肉疏松和消瘦综合征或疾病）和治疗炎症和免疫失调的方法。